WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

WMT

87.28

-2.88%↓

COST

968.19

+0.2%↑

TGT

94.31

-10.89%↓

KR

70.66

+5.01%↑

GIS

61.01

+3.04%↑

Search

Hims & Hers Health Inc

Closed

SectorConsumer defensive

27.92 -10.34

Overview

Share price change

24h

Current

Min

27.74

Max

29.8

Key metrics

By Trading Economics

Income

-50M

26M

Sales

80M

481M

P/E

Sector Avg

54.722

44.466

EPS

0.227

Profit margin

5.409

Employees

1,637

EBITDA

-8.2M

19M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+49.76% upside

Dividends

By Dow Jones

Next Earnings

5 May 2025

Market Stats

By TradingEconomics

Market Cap

-4.7B

6.5B

Previous open

38.26

Previous close

27.92

News Sentiment

By Acuity

18%

82%

9 / 152 Consumer defensive

Technical Score

By Trading Central

Confidence

Bearish Evidence

Hims & Hers Health Inc Chart

Past performance is not a reliable indicator of future results.

Related News

1 Apr 2025, 23:15 UTC

Major Market Movers

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 Feb 2025, 15:33 UTC

Major Market Movers

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 Nov 2024, 19:07 UTC

Major Market Movers

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 Oct 2024, 15:02 UTC

Major Market Movers

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

3 Oct 2024, 11:28 UTC

Major Market Movers

Hims & Hers Health Shares Fall After FDA Removes Eli Lilly Obesity Drugs From Shortage List

2 Apr 2025, 16:53 UTC

Top News

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 Mar 2025, 15:54 UTC

Top News

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 Feb 2025, 23:20 UTC

Earnings

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 Feb 2025, 12:00 UTC

Top News

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 Dec 2024, 17:16 UTC

Top News

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 Dec 2024, 15:14 UTC

Top News

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 Dec 2024, 15:02 UTC

Top News

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 Dec 2024, 13:47 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 Dec 2024, 07:00 UTC

Top News

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 Oct 2024, 14:45 UTC

Top News

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 Oct 2024, 13:12 UTC

Top News

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 Oct 2024, 11:45 UTC

Top News

Update: Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 Oct 2024, 10:14 UTC

Top News

Update: Eli Lilly's Weight-Loss Drugs No Longer In Shortage. It's Bad News for These Stocks. -- Barrons.com

2 Aug 2024, 17:52 UTC

Acquisitions, Mergers, Takeovers

Hims & Hers Plan to Sell Knockoff Weight Loss Drug Looking Shaky -- Barrons.com

26 Jun 2024, 11:00 UTC

Top News
Acquisitions, Mergers, Takeovers

The War Over Cheaper Ozempic Won't End Well for Some Investors -- Heard on the Street -- WSJ

24 May 2024, 20:37 UTC

Earnings

The Score: Target, Nvidia, Live Nation and More Stocks That Defined the Week -- WSJ

Peer Comparison

Price change

Hims & Hers Health Inc Forecast

Price Target

By TipRanks

49.76% upside

12 Months Forecast

Average 46.5 USD  49.76%

High 85 USD

Low 21 USD

Based on 13 Wall Street analysts offering 12 month price targets forHims & Hers Health Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

13 ratings

5

Buy

6

Hold

2

Sell

Technical Score

By Trading Central

31.0237 / 31.88Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

9 / 152 Consumer defensive

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.